Searchable abstracts of presentations at key conferences in endocrinology

ea0077p140 | Adrenal and Cardiovascular | SFEBES2021

Should the 1 mg -overnight dexamethasone suppression test be repeated in patients with benign adrenal incidentalomas and no overt hormone excess?

Narayanan Rengarajan Lakshmi , Knowles Gregory , Asia Miriam , Elhassan Yasir S , Arlt Wiebke , Ronchi Cristina L , Prete Alessandro

Background: Benign adrenal incidentalomas (AI) are found in 3-5% of adults. All patients should undergo a 1 mg -overnight dexamethasone suppression test (1 mg -DST) to exclude cortisol excess (non-functioning adrenal tumours, NFAT; serum cortisol ≤50 nmol/l) or diagnose possible mild autonomous cortisol secretion (MACS; serum cortisol >50 nmol/l). Current guidelines discourage repeating hormonal work-up in patients with benign AI. However, data underpinning this reco...

ea0063gp188 | Adrenal and Neuroendocrine - Clinical | ECE2019

Increased risk of infections in Addison’s disease and congenital adrenal hyperplasia patients: a longitudinal study based on a United Kingdom primary care database

Tresoldi Alberto S , Sumilo Dana , Perrins Mary , Toulis Konstantinos A , Prete Alessandro , Reddy Narendra , Wass John A , Nirantharakumar Krishnarajah , Arlt Wiebke

Background: Primary adrenal insufficiency (PAI) can be of autoimmune origin (Addison’s disease, AD) or due to inborn disorders of steroidogenesis (congenital adrenal hyperplasia, CAH). Prognosis of patients with PAI has improved considerably after glucocorticoid replacement therapy became available. However, even in recent years, an increased risk of death has been described in both AD and CAH patients. Moreover, even with the current state-of-the-art replacement therapy,...

ea0059p015 | Adrenal and steroids | SFEBES2018

Natural history of adrenal incidentalomas with and without mild autonomous cortisol excess; a systematic review and meta-analysis

Elhassan Yasir , Alahdab Fares , Prete Alessandro , Delivanis Danae , Khanna Aakanksha , Murad Mohammad , O'Reilly Michael , Arlt Wiebke , Bancos Irina

Background: Adrenal incidentalomas are mostly non-functioning adrenal tumours (NFAT) or adenomas with mild autonomous cortisol excess (MACE), of which the natural history is unclear. We conducted a systematic review and meta-analysis focussing on NFAT and MACE to determine the: (i) proportion and degree of tumour growth, (ii) incident change in hormone function, and (iii) proportion of malignant transformation.Methods: We searched MEDLINE In-Process &#38...

ea0035p1140 | Thyroid Cancer | ECE2014

Thyroglobulin before radio remnant ablation during levothyroxine withdrawal can be considered an accurate parameter of remission of differentiated thyroid cancer

Paragliola Rosa Maria , De Rosa Annapina , Di Donna Vincenzo , Locantore Pietro , Senes Paola , Prete Alessandro , Pontecorvi Alfredo , Corsello Salvatore Maria

Introduction: Differentiated thyroid cancer (DTC) is the most frequent endocrine cancer. After surgery followed, if any, by 131I radio remnant ablation (RRA), follow-up monitoring consists of neck ultrasonography (US) and measurements of thyroglobulin (Tg) levels and anti-Tg antibodies (Ac-Tg) both on levothyroxine (L-T4) therapy and after recombinant TSH (rTSH). The aim of our study is to define a cut-off of Tg before RRA (RRA-Tg) during <...

ea0075a21 | Adrenal gland | EYES2021

Impact of COVID-19 on patients with primary adrenal insufficiency: A cross-sectional study

Knowles Gregory , Warmington Emily , Shepherd Lisa , Hazlehurst Jonathan , De Bray Anne , Gleeson Helena , Arlt Wiebke , Prete Alessandro

Background: Patients with primary adrenal insufficiency (PAI) carry an increased risk of infections which can precipitate adrenal crises. They are thought to be more likely to contract COVID-19 and develop severe disease; however, little is known about the true impact of COVID-19 on these patients.Objectives: To assess the response of a large single-centre cohort of PAI patients to COVID-19, focusing on morbidity and health promotion attitudes.<p cla...

ea0084ps1-03-21 | Thyroid Cancer CLINICAL 1 | ETA2022

Risk of structural recurrence in differentiated thyroid carcinoma (DTC) patients without evidence of disease after initial treatment: insights into risk factors and comparison with american thyroid association guidelines

Contartese Lea , Gambale Carla , Prete Alessandro , Puleo Luciana , Cappagli Virginia , Lorusso Loredana , Agate Laura , Molinaro Eleonora , Elisei Rossella , Matrone Antonio

Background: The last American Thyroid Association guidelines (ATA-2015) defined the risk of structural recurrence in patients with DTC cured after initial treatment and according to the initial histology. However, these data resulted from several studies including different patients with different kinds of treatment. We retrospectively evaluated a large population of patients with DTC, treated and followed in a tertiary referral center, with the aim to characterize the rate of...

ea0084ps3-15-140 | Thyroid Cancer Diagnosis & Treatment | ETA2022

Basal calcitonin as guide for an early and safe thyroid surgery in RET gene carriers

Prete Alessandro , Gambale Carla , Bottici Valeria , Cappagli Virginia , Matrone Antonio , Materazzi Gabriele , Basolo Fulvio , Romei Cristina , Elisei Rossella

Introduction: Virtually all familial cases of Medullary Thyroid Carcinoma (MTC) have a RET germline mutation. Subjects harboring RET germline mutation without unaware of their condition are defined gene carriers (GC). Thyroid surgery timing is decided upon RET mutation and calcitonin levels (both basal, bCT, and stimulated, sCT). However, bCT and sCT thresholds for planning thyroid surgery have not been established, yet.Methods...

ea0086p9 | Adrenal and Cardiovascular | SFEBES2022

Inflammation-Based Scores as Predictors of Treatment Response in Advanced Adrenocortical Carcinoma

Mangone Alessandra , S. Elhassan Yasir , Prete Alessandro , Asia Miriam , Detomas Mario , Altieri Barbara , Mantovani Giovanna , Ronchi Cristina L.

Background: Standard treatment for advanced adrenocortical carcinoma (ACC) is mitotane in monotherapy or combined with etoposide, doxorubicin and cisplatin (EDP), yet biomarkers predictive of treatment response are lacking. Inflammation-based scores were proposed as predictors for gemcitabine+capecitabine efficacy, used as second-line in progressive ACC. We investigated the role of inflammation-based scores in predicting response to first-line treatment in advanced ACC.<p ...

ea0086p12 | Adrenal and Cardiovascular | SFEBES2022

Phaeochromocytomas Most Commonly Present As Adrenal Incidentalomas – A Large Tertiary Centre Experience

Aggarwal Sunil , Prete Alessandro , Asia Miriam , Arlt Wiebke , Ronchi Cristina , Sutcliffe Robert , Karavitaki Niki , Ayuk John , Elhassan Yasir

Background: The detection of phaeochromocytomas evolved from autopsy finding to presentation in symptomatic/hypertensive, and genetically-predisposed individuals. Increasingly, phaeochromocytomas are diagnosed in incidental adrenal masses and the impact on the clinical, biochemical, and radiological features is unclear.Methods: Retrospective review of patients with phaeochromocytomas seen at a large tertiary referral centre between January 2010 and May 2...

ea0077oc4.5 | Adrenal and Cardiovascular | SFEBES2021

Circulating cell-free DNA-based biomarkers as a tool for disease surveillance in adrenocortical carcinoma

Smith Gabrielle , Lippert Juliane , Altieri Barbara , Elhassan Yasir , Landwehr Laura , Prete Alessandro , Appenzeller Silke , Chortis Vasileios , Steinhauer Sonja , Asia Miriam , Sutcliffe Robert , Arlt Wiebke , Fassnacht Martin , Ronchi Cristina

Adrenocortical carcinoma (ACC) is a rare aggressive cancer with heterogeneous behaviour. Disease surveillance relies on frequent imaging, which comes with significant radiation exposure. Here we investigated the role of circulating cell-free DNA (ccfDNA) in ACC monitoring. We extracted ccfDNA from 1-4 ml EDTA-plasma using the Nonacus Cell3TMXtract or the Qiagen QIAamp MinElute kit and quantified by fluorimeter. We investigated 63 patients with ACC (25M/38F, 52±...